RT @Varro_Analytics: Percent of #cysticfibrosis population that each $VRTX drug can treat: 14% - Kalydeco (Ivacaftor, approved 2012): 28%…
Percent of #cysticfibrosis population that each $VRTX drug can treat: 14% - Kalydeco (Ivacaftor, approved 2012): 28% - Orkambi (lumacaftor + tezacaftor, 2018): 90% - Trikafta (elexacaftor + ivacaftor + tezacaftor, 2019): https://t.co/DK3GfGDYxT https
@DrMJoyner @beryl_bbc Trying to find some refs, but this looks interesting https://t.co/2KuJ06oA8d , https://t.co/TqCUzkYqsV
RT @CDC_Genomics: Read CDC BLOG: Evaluating the impact of precision medicine: How Ivacaftor reduces hospitalizations of patients with cysti…
Read CDC BLOG: Evaluating the impact of precision medicine: How Ivacaftor reduces hospitalizations of patients with cystic fibrosis. https://t.co/HrdaRoWBkW https://t.co/e8lDp2FW9G
RT @Health_Affairs: A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuC…
A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuCAO8yGu https://t.co/Linff85Nlk
Sterke afname (tot 87%) van opnames voor CF na start ivacaftor. https://t.co/UAar4seGwD
RT @Health_Affairs: A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuC…
RT @Health_Affairs: A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuC…
A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuCAO8yGu https://t.co/BCGHaSGkSB
RT @Health_Affairs: A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuC…
RT @Health_Affairs: A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuC…
A case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis @CF_Foundation https://t.co/jSuCAO8yGu https://t.co/tHRwiP7SI1
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
Super important points in this presentation made by my wicked smart friend and colleague @lbfeng #CFAdvocacy 👇🏻 https://t.co/sQOyxGw0BB
Precision Medicine In Action: The Impact Of Ivacaftor On #CysticFibrosis Related Hospitalizations #CF #lung https://t.co/r038BT9Npm https://t.co/HCllGbC2al
@wiise_usa @SarahWieten @Health_Affairs I was skeptical until this month's issue of Health Affairs, themed on precision medicine with a bunch of good articles. Example that makes me think precision medicine can live up to promises: precision med treatment
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
RT @G17Esiason: This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for…
This is the kind of thing @NHSEngland needs to be looking at for #OrkambiNow - inpatient costs are significantly lower for patients on CFTR Modulators (also not quantified is improved quality of life by not being inpatient) - I’d like to see similar study
RT @DrKhouryCDC: Read new CDC paper on the impact of ivacaftor on reducing cystic fibrosis-related hospitalizations. #precisionmedicine htt…
Read new CDC paper on the impact of ivacaftor on reducing cystic fibrosis-related hospitalizations. #precisionmedicine https://t.co/sRM1QrHJH4 https://t.co/ZjpWBZ8xvm
ICYMI: #personalizedmedicine resulted in fewer inpatient hospitalizations & lower inpatient spending. Talk about value for patients AND the health are system! https://t.co/2TLkOva6Av
RT @lbfeng: Hot off the press! Great day at the National Press Club. Tx @Health_Affairs https://t.co/uvwlQ1btEF
RT @lbfeng: Hot off the press! Great day at the National Press Club. Tx @Health_Affairs https://t.co/uvwlQ1btEF
RT @lbfeng: Hot off the press! Great day at the National Press Club. Tx @Health_Affairs https://t.co/uvwlQ1btEF
Hot off the press! Great day at the National Press Club. Tx @Health_Affairs https://t.co/uvwlQ1btEF
RT @Health_Affairs: Lisa Feng @CF_Foundation shares a case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis h…
Lisa Feng @CF_Foundation shares a case of #PrecisionMedicine in action- expanded use of Ivacaftor for #cysticfibrosis https://t.co/jSuCAOqa54 https://t.co/1lAUoNdbNS